Comparing when anti-PD-1 treatment starts in high-risk early-stage melanoma
Compares outcomes in melanoma patients given anti-PD-1 before or after surgery.
Plain-language title generated from the registry record
Registry title: NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
Key facts
- Where
- São Paulo, BrazilSee the site
Where in Brazil
- AC Camargo Cancer CenterSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AC Camargo Cancer Center
- Trial code
- NCT07680699
- Record updated
- 2 July 2026
- Original description
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.Read full original descriptionShow less
NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And/Or Microsatellitosis: An Ambispective Observational Cohort Study
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.
Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.
The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice.
No treatments are assigned as part of the study.
Inclusion: Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.
Exclusion: Patients without sufficient clinical or follow-up data; Patients who do not provide informed consent (for prospective cohort).